

“Stability Indicating Method for Simultaneous Estimation of Linagliptin and Metformin hydrochloride in their Combine Dosage form”

Submitted By

Chauhan Asefa I

Supervised By

Dr. PriyankaPatil

Assistant Professor,

Dept. of Quality Assurance

Parul Institute of Pharmacy and Research

Limda, Ta. Waghodia, Dist. Vadodara 391760

Abstract

The simple, specific, accurate, precise and reproducible methods have been developed and validated for the simultaneous estimation of both drugs in their combined dosage form. In RP-HPLC, analysis is carried out using Buffer (KH₂PO₄ 50mM 4.5 pH): Methanol (55:45 %v/v) pH 4.5 adjusted by Orthophosphoric acid) mobile phase and BDS hypersil C₁₈, 250mm × 4.6mm, 5μ (particle size), Thermo scientific as stationary phase with detection wavelength of 232 nm. Linearity was obtained in the concentration range of 5-15μg/ml and 50-150 μg/ml for Linagliptin and Metformin Hydrochloride respectively. The % recoveries of the both the drugs were found to be 99.81-100.21% and 99.74-100.15% respectively. LOD were found to be 0.18 μg/ml and 6.24μg/ml at 232 nm for Linagliptin and Metformin Hydrochloride respectively. Methods were statistically validated for accuracy, precision, specificity, LOQ, robustness and ruggedness according to ICH guidelines and can be used for analysis of combined dosage form.

Key Words: RP-HPLC, Force degradation study, Linagliptin and Metformin Hydrochloride